Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease

Neurobiology of Aging

Volumn 33, Issue 7, 2012, Pages 1329-1342

  Ferretti, Maria Teresa ^a   Bruno, Martin A ^a   Ducatenzeiler, Adriana ^a   Klein, William L ^b   Cuello, A Claudio ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

A oligomers; COX 2; Inflammation; INOS; Preclinical Alzheimer's disease

Indexed keywords

AMYLOID BETA PROTEIN; CD40 ANTIGEN; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN PERFUSION; CELL ACTIVATION; CELL STRUCTURE; CONTROLLED STUDY; HIPPOCAMPAL CA1 REGION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; UPREGULATION; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; INFLAMMATION; INTRACELLULAR FLUID; MICE; MICE, TRANSGENIC; MICROGLIA; TIME FACTORS;

EID: 84861183285     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.01.007     Document Type: Article

References (74)

1. Abbas N., Bednar I., Mix E., Marie S., Paterson D., Ljungberg A., Morris C., Winblad B., Nordberg A., Zhu J. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J. Neuroimmunol 2002, 126:50-57.
2. Ahmed Z., Shaw G., Sharma V.P., Yang C., McGowan E., Dickson D.W. Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J. Histochem. Cytochem 2007, 55:687-700.
3. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826.
4. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I.Van, Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
5. Andersen K., Launer L.J., Ott A., Hoes A.W., Breteler M.M., Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?. The Rotterdam Study. Neurology 1995, 45:1441-1445.
6. Breitner J.C. Treatment Effects of NSAIDs Related to Stage of Alzheimer's Disease Pathogenesis-Lessons from ADAPT. 9th International Conference of Alzheimer's Disease 2009.
7. Brown G.C., Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol 2003, 27:325-355.
8. Bruno M.A., Leon W.C., Fragoso G., Mushynski W.E., Almazan G., Cuello A.C. Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease. J. Neuropathol. Exp. Neurol 2009, 68:857-869.
9. Bruno M.A., Mufson E.J., Wuu J., Cuello A.C. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J. Neuropathol. Exp. Neurol 2009, 68:1309-1318.
10. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., Jones T., Banati R.B. In-vivo measurement of activated microglia in dementia. Lancet 2001, 358:461-467.
11. Cuello A.C. Overview of the Alzheimer's Disease Pathology and Potential Therapeutic Targets. Pharmacological Mechanisms in Alzheimer's Therapeutics 2007, Springer, New York. A.C. Cuello (Ed.).
12. da Silva R.P., Gordon S. Phagocytosis stimulates alternative glycosylation of macrosialin (mouse CD68), a macrophage-specific endosomal protein. Biochem. J 1999, 338:687-694.
13. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci 2008, 9:46-56.
14. Dawson V.L., Dawson T.M., London E.D., Bredt D.S., Snyder S.H. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:6368-6371.
15. Ferretti M.T., Partridge V., Leon W.C., Canneva F., Allard S., Arvanitis D., Vercauteren F., Houle J.D., Ducatenzeiler A., Klein W., Glabe C., Cuello A.C. Transgenic mice as a model of pre-clinical Alzheimer's disease. Curr. Alzheimer Res 2010, Epub ahead of print.
16. Floden A.M., Combs C.K. Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J. Neurosci 2006, 26:4644-4648.
17. Fuhrmann M., Bittner T., Jung C.K., Burgold S., Page R.M., Mitteregger G., Haass C., LaFerla F.M., Kretzschmar H., Herms J. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci 2010, 13:411-413.
18. Good P.F., Werner P., Hsu A., Olanow C.W., Perl D.P. Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol 1996, 149:21-28.
19. Grant S.M., Ducatenzeiler A., Szyf M., Cuello A.C. Abeta immunoreactive material is present in several intracellular compartments in transfected, neuronally differentiated, P19 cells expressing the human amyloid beta-protein precursor. J Alzheimers Dis 2000, 2:207-222.
20. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci 2007, 10:1387-1394.
21. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Dewachter I., Walter J., Klockgether T., Van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J. Neuroinflammation 2005, 2:22.
22. Herrup K., Yang Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology?. Nat. Rev. Neurosci 2007, 8:368-378.
23. Holmin S., Mathiesen T. Long-term intracerebral inflammatory response after experimental focal brain injury in rat. Neuroreport 1999, 10:1889-1891.
24. Holtzman J.L. Are we prepared to deal with the Alzheimer's disease pandemic?. Clin. Pharmacol. Ther 2010, 88:563-565.
25. Hoozemans J.J., Bruckner M.K., Rozemuller A.J., Veerhuis R., Eikelenboom P., Arendt T. Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J. Neuropathol. Exp. Neurol 2002, 61:678-688.
26. Hu L., Wong T.P., Cote S.L., Bell K.F., Cuello A.C. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice. Neuroscience 2003, 121:421-432.
27. Iadecola C., Forster C., Nogawa S., Clark H.B., Ross M.E. Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol 1999, 98:9-14.
28. Janelsins M.C., Mastrangelo M.A., Oddo S., LaFerla F.M., Federoff H.J., Bowers W.J. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J. Neuroinflammation 2005, 2:23.
29. Klegeris A., McGeer P.L. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr. Alzheimer Res 2005, 2:355-365.
30. Kotilinek L.A., Westerman M.A., Wang Q., Panizzon K., Lim G.P., Simonyi A., Lesne S., Falinska A., Younkin L.H., Younkin S.G., Rowan M., Cleary J., Wallis R.A., Sun G.Y., Cole G., Frautschy S., Anwyl R., Ashe K.H. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 2008, 131:651-664.
31. Lambert M.P., Velasco P.T., Chang L., Viola K.L., Fernandez S., Lacor P.N., Khuon D., Gong Y., Bigio E.H., Shaw P., De Felice F.G., Krafft G.A., Klein W.L. Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem 2007, 100:23-35.
32. Lee C.Y., Landreth G.E. The role of microglia in amyloid clearance from the AD brain. J. Neural Transm 2010, 117:949-960.
33. Luth H.J., Holzer M., Gartner U., Staufenbiel M., Arendt T. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res 2001, 913:57-67.
34. Lyketsos C.G., Breitner J.C., Green R.C., Martin B.K., Meinert C., Piantadosi S., Sabbagh M. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68:1800-1808.
35. Majdi M., Ribeiro-da-Silva A., Cuello A.C. Cognitive impairment and transmitter-specific pre- and postsynaptic changes in the rat cerebral cortex during ageing. Eur. J. Neurosci 2007, 26:3583-3596.
36. Malm T.M., Koistinaho M., Parepalo M., Vatanen T., Ooka A., Karlsson S., Koistinaho J. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis 2005, 18:134-142.
37. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-346.
38. Martin B.K., Szekely C., Brandt J., Piantadosi S., Breitner J.C., Craft S., Evans D., Green R., Mullan M. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol 2008, 65:896-905.
39. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M., Olschowka J.A., Fonseca M.I., O'Banion M.K., Tenner A.J., Lemere C.A., Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol 2001, 158:1345-1354.
40. McGeer P.L., McGeer E., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990, 335:1037.
41. McGeer P.L., Rogers J., McGeer E.G. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J. Alzheimers Dis 2006, 9:271-276.
42. Meinert C.L., McCaffrey L.D., Breitner J.C. Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement 2009, 5:93-104.
43. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol 2004, 63:901-910.
44. Morgan D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol. Disord. Drug Targets 2009, 8:7-15.
45. Morris J.C., Price A.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci 2001, 17:101-118.
46. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol 2001, 58:397-405.
47. Murphy G.M., Zhao F., Yang L., Cordell B. Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer's disease. Am. J. Pathol 2000, 157:895-904.
48. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
49. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol 2001, 60:759-767.
50. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., LaFerla F.M. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem 2006, 281:1599-1604.
51. Okello A., Edison P., Archer H.A., Turkheimer F.E., Kennedy J., Bullock R., Walker Z., Kennedy A., Fox N., Rossor M., Brooks D.J. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009, 72:56-62.
52. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998, 87:319-324.
53. Petersen R.C. Early diagnosis of Alzheimer's disease: is MCI too late?. Curr. Alzheimer Res 2009, 6:324-330.
54. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol 1999, 56:303-308.
55. Qiao X., Cummins D.J., Paul S.M. Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur. J. Neurosci 2001, 14:474-482.
56. Quinn J., Montine T., Morrow J., Woodward W.R., Kulhanek D., Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J. Neuroimmunol 2003, 137:32-41.
57. Reichert F., Rotshenker S. Deficient activation of microglia during optic nerve degeneration. J. Neuroimmunol 1996, 70:153-161.
58. Rotshenker S. The role of Galectin-3/MAC-2 in the activation of the innate-immune function of phagocytosis in microglia in injury and disease. J. Mol. Neurosci 2009, 39:99-103.
59. Santambrogio L., Belyanskaya S.L., Fischer F.R., Cipriani B., Brosnan C.F., Ricciardi-Castagnoli P., Stern L.J., Strominger J.L., Riese R. Developmental plasticity of CNS microglia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6295-6300.
60. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12013-12017.
61. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev 2001, 81:741-766.
62. Semenenko F.M., Bramwell S., Sidebottom E., Cuello A.C. Development of a mouse antiperoxidase secreting hybridoma for use in the production of a mouse PAP complex for immunocytochemistry and as a parent cell line in the development of hybrid hybridomas. Histochemistry 1985, 83:405-408.
63. Sheng J.G., Bora S.H., Xu G., Borchelt D.R., Price D.L., Koliatsos V.E. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol. Dis 2003, 14:133-145.
64. Simard A.R., Soulet D., Gowing G., Julien J.P., Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006, 49:489-502.
65. Smith M.A., Richey-Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci 1997, 17:2653-2657.
66. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48:626-632.
67. Tan J., Town T., Paris D., Mori T., Suo Z., Crawford F., Mattson M.P., Flavell R.A., Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999, 286:2352-2355.
68. Teather L.A., Packard M.G., Bazan N.G. Post-training cyclooxygenase-2 (COX-2) inhibition impairs memory consolidation. Learn. Mem 2002, 9:41-47.
69. Thal L.J., Ferris S.H., Kirby L., Block G.A., Lines C.R., Yuen E., Assaid C., Nessly M.L., Norman B.A., Baranak C.C., Reines S.A. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005, 30:1204-1215.
70. Wong M.L., Rettori V., al-Shekhlee A., Bongiorno P.B., Canteros G., McCann S.M., Gold P.W., Licinio J. Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nat. Med 1996, 2:581-584.
71. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993, 11:371-386.
72. Yang A.J., Chandswangbhuvana D., Shu T., Henschen A., Glabe C.G. Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42. J. Biol. Chem 1999, 274:20650-20656.
73. Yokota C., Kaji T., Kuge Y., Inoue H., Tamaki N., Minematsu K. Temporal and topographic profiles of cyclooxygenase-2 expression during 24 h of focal brain ishemia in rats. Neurosci. Lett 2004, 357:219-222.
74. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.